Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Schmitt, Anita  [Clear All Filters]
2024
Han H, Wang L, Ding Y, Neuber B, Hueckelhoven-Krauss AGabriele, Lin M, Yao H, Chen Q, Sauer T, Schubert M-L, et al. Extracorporeal photopheresis as a promising strategy for the treatment of GvHD after CAR-T cell therapy. Blood Adv. 2024.
2023
Korell F, Schönland S, Schmitt A, Jansen M, Farid K, Müller-Tidow C, Dreger P, Schmitt M, Hegenbart U. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma. Biomark Res. 2023;11(1):91.
John L, Sauer S, Hegenbart U, Dreger P, Hundemer M, Müller-Tidow C, Schmitt A, Schmitt M, Raab MS, Schönland SO. Idecabtagene vicleucel is well tolerated and effective in relapsed/refractory myeloma patients with prior allogeneic stem cell transplantation. Transplant Cell Ther. 2023.
Kauer J, Freundt EP, Schmitt A, Weinhold N, Mai EK, Müller-Tidow C, Goldschmidt H, Raab MS, Kriegsmann K, Sauer S. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. BMC Cancer. 2023;23(1):1132.
Schubert M-L, Schmitt A, Hückelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, Vonficht D, Yousefian S, Jopp-Saile L, Wang L, et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol. 2023;16(1):79.
2022
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2022.
2021
Sauer S, Erdmann K, Jensen AD, Wennmann M, Pavel P, Jordan K, Schmitt A, Kriegsmann M, Wuchter P, Goldschmidt H, et al. Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients. Transplant Cell Ther. 2021.
2020
Schuber M-L, Dietrich S, Stilgenbauer S, Schmitt A, Pavel P, Kunz A, Bondong A, Wegner M, Stadtherr P, Jung S, et al. Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Krummradt F, Sauer S, Pavel P, Klein E-M, Schmitt A, Kriegsmann M, Jordan K, Müller-Tidow C, Goldschmidt H, Wuchter P, et al. Storage, Utilization and Disposal of Hematopoietic Stem Cell Products in Multiple Myeloma Patients. Biol Blood Marrow Transplant. 2020.
2018
Kriegsmann K, Wack M, Pavel P, Schmitt A, Kriegsmann M, Bruckner T, Müller-Tidow C, Wuchter P. Collection, cryostorage, transplantation and disposal of hematopoietic stem cell products. Biol Blood Marrow Transplant. 2018.
2016
Schubert M-L, Hückelhoven AGabriele, Hoffmann J-M, Schmitt A, Wuchter P, Sellner L, Hofmann S, Ho AD, Dreger P, Schmitt M. Chimeric antigen receptor (CAR) T cell therapy targeting CD19 positive leukemia and lymphoma in the context of stem cell transplantation. Hum Gene Ther. 2016.
Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, et al. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget. 2016.
2015
Lisenko K, Stadtherr P, Bruckner T, Pavel P, Heilig C, Schmitt A, Puthenparambil J, Brandt J, Ho AD, Dreger P, et al. Bone marrow harvesting of allogeneic donors in an outpatient setting: a single-center experience. Biol Blood Marrow Transplant. 2015.
Casalegno-Garduño R, Schmitt A, Spitschak A, Greiner J, Wang L, Hilgendorf I, Hirt C, Ho AD, Freund M, Schmitt M. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation. Int J Cancer. 2015.